TheraRadar
Data updated: May 26, 2026

JAVADIN (clonidine hydrochloride)

Cardiovascular Approved 2025-10-23

Javadin helps adult patients with high blood pressure by lowering their readings to safer levels. Reducing blood pressure with this medication helps decrease the risk of cardiovascular events, such as strokes and heart attacks. It is often used as part of a comprehensive management plan that includes lifestyle changes and other medications to reach specific cardiovascular goals.

Source: FDA Label • AZURITY

How JAVADIN Works

This medication works by

1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-10-23
Patent Cliff
2042

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: CLONIDINE HYDROCHLORIDE

JAVADIN Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Oct 2025 ORIGINAL
New Form · Type 3 - New Dosage Form

What JAVADIN Treats

3 indications

JAVADIN is approved for 3 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
  • Stroke
  • Myocardial Infarction
Source: FDA Label

JAVADIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to JAVADIN

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
3 shared
PH HEALTH
ATENOLOL
ATENOLOL
3 shared
NOSTRUM LABS
ATENOLOL AND CHLORTHALIDONE
ATENOLOL
3 shared
NOVITIUM PHARMA
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01439126 results posted SHN-KAP-401 Ph 4 completed Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

JAVADIN FDA Label Details

Indications & Usage

FDA Label (PDF)

JAVADIN is indicated for the treatment of Hypertension; Stroke; Myocardial Infarction.

View full patent landscape →
2 OB patents · 1 families · 5 international docs across 1 countries

JAVADIN Patents & Exclusivity

Latest Patent: Jul 2042

Patents (2 active)

US12233049 Expires Jul 15, 2042
US12440474 Expires Jul 15, 2042
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for JAVADIN

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2042
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.